140 related articles for article (PubMed ID: 30367632)
1. Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery.
McCool KW; Sampene E; Polnaszek B; Connor J; Medlin EE; Barroilhet L
BMC Cancer; 2018 Oct; 18(1):1041. PubMed ID: 30367632
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
O'Shea A; McCool K; Harrison R; Sampene E; Connor J; Barroilhet L
Gynecol Oncol; 2018 Jul; 150(1):19-22. PubMed ID: 29773300
[TBL] [Abstract][Full Text] [Related]
3. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
4. Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
Connor JP; O'Shea A; McCool K; Sampene E; Barroilhet LM
Gynecol Oncol; 2018 Nov; 151(2):294-298. PubMed ID: 30201233
[TBL] [Abstract][Full Text] [Related]
5. Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
Manning-Geist BL; Alimena S; Del Carmen MG; Goodman A; Clark RM; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Gynecol Oncol; 2019 Apr; 153(1):63-67. PubMed ID: 30635213
[TBL] [Abstract][Full Text] [Related]
6. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
8. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
9. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer.
De Oliveira GS; Schink JC; Buoy C; Ahmad S; Fitzgerald PC; McCarthy RJ
Transfus Med; 2012 Apr; 22(2):97-103. PubMed ID: 22151920
[TBL] [Abstract][Full Text] [Related]
10. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer.
Phillips A; Sundar S; Singh K; Nevin J; Elattar A; Kehoe S; Balega J
Eur J Surg Oncol; 2018 Jun; 44(6):760-765. PubMed ID: 29426779
[TBL] [Abstract][Full Text] [Related]
11. Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
Shin W; Noh JJ; Seo SS; Kang S; Choi CH; Park SY; Kim BG; Lim MC
Yonsei Med J; 2020 Nov; 61(11):935-941. PubMed ID: 33107236
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
Meyer LA; He W; Sun CC; Zhao H; Wright AA; Suidan RS; Dottino J; Alejandro Rauh-Hain J; Lu KH; Giordano SH
Gynecol Oncol; 2018 Sep; 150(3):451-459. PubMed ID: 29961559
[TBL] [Abstract][Full Text] [Related]
13. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
[TBL] [Abstract][Full Text] [Related]
14. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.
Petrillo M; Nero C; Carbone V; Bruno M; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Jan; 25(1):247-254. PubMed ID: 29134372
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer.
Bogani G; Ditto A; Leone Roberti Maggiore U; Scaffa C; Mosca L; Chiappa V; Martinelli F; Lorusso D; Raspagliesi F
Tumori; 2019 Feb; 105(1):92-97. PubMed ID: 29984612
[TBL] [Abstract][Full Text] [Related]
17. Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.
Ackroyd SA; Thomas S; Angel C; Moore R; Meacham PJ; DuBeshter B
J Robot Surg; 2018 Jun; 12(2):245-250. PubMed ID: 28631233
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
Ihemelandu C; Mavros MN; Sugarbaker P
Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
[TBL] [Abstract][Full Text] [Related]
19. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
20. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.
Chalfin HJ; Liu JJ; Gandhi N; Feng Z; Johnson D; Netto GJ; Drake CG; Hahn NM; Schoenberg MP; Trock BJ; Scott AV; Frank SM; Bivalacqua TJ
Ann Surg Oncol; 2016 Aug; 23(8):2715-22. PubMed ID: 27012987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
